1075-11-2

Basic information

• Product Name: 6-FLUOROISOQUINOLINE
• Synonyms: 6-FLUOROISOQUINOLINE
• CAS NO: 1075-11-2
• Molecular Formula: C₉H₆FN
• Molecular Weight: 147.15
• Mol File: 1075-11-2.mol

Chemical Properties

• Melting Point: 48-50℃
• Boiling Point: 255.265 °C at 760 mmHg
• Flash Point: 108.181 °C
• Appearance: /
• Density: 1.216 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 5.27±0.10(Predicted)
• CAS DataBase Reference: 6-FLUOROISOQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-FLUOROISOQUINOLINE(1075-11-2)
• EPA Substance Registry System: 6-FLUOROISOQUINOLINE(1075-11-2)

Safety Data

• Hazardous Substances Data: 1075-11-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
6-Fluoroisoquinoline is used as a key precursor in the synthesis of various drugs and agrochemicals for its ability to enhance the biological activity and therapeutic potential of the resulting compounds.
Used in Research and Development:
6-Fluoroisoquinoline is utilized as a starting material in the creation of new molecules with potential therapeutic benefits, contributing to the advancement of medicine and healthcare.
Used in Analytical Chemistry and Bioimaging:
6-Fluoroisoquinoline is employed as a fluorescent probe, enabling the detection, analysis, and visualization of specific molecules or biological processes in various analytical and imaging techniques.

Upstream product

• 918488-54-7 N-(2,2-dimethoxy-ethyl)-N-(4-fluoro-benzyl)-4-methyl-benzene-sulfonamide 
• 7651-82-3 isoquinolin-6-ol 
• 700-84-5 5-fluoro-1-indanone 
• 52163-88-9 6-fluoro-1H-indene 
• 52085-92-4 5-fluoro-2,3-dihydro-1H-inden-1-ol 
• 459-57-4 4-fluorobenzaldehyde 
• 34784-05-9 6-bromo-isoquinoline 

Downstream Products

• 1416500-78-1 4-bromo-6-fluoro-isoquinoline 
• 214045-86-0 1-chloro-6-fluoroisoquinoline 
• 119-65-3 isoquinoline 
• 608515-77-1 6-fluoro-1-methylisoquinoline 
• 214045-85-9 6-fluoro-1,2-dihydroisoquinolin-1-one 
• 1239463-43-4 5-bromo-6-fluoroisoquinoline 

Relevant articles and documents

Synthesis of Indole-Dihydroisoquinoline Sulfonyl Ureas via Three-Component Reactions

Isoquinolines activated with sulfamoyl chlorides were reacted with indoles in a 3-component reaction to generate a library of dihydroisoquinoline derivatives. Using a differential protecting group strategy, products could be further derivatised. Synthesis of isoquinoline starting materials using several different methods is also described.

PhenoFluor: Practical synthesis, new formulation, and deoxyfluorination of heteroaromatics

We report a practical synthesis method of the reagent PhenoFluor on decagram scale, provide a new formulation of PhenoFluor as a toluene solution, which should decrease challenges associated with the moisture sensitivity of the reagent, and expand the substrate scope of deoxyfluorination with PhenoFluor to heteroaromatics.

Pd-catalyzed nucleophilic fluorination of aryl bromides

On the basis of mechanism-driven reaction design, a Pd-catalyzed nucleophilic fluorination of aryl bromides and iodides has been developed. The method exhibits a broad substrate scope, especially with respect to nitrogen-containing heteroaryl bromides, and proceeds with minimal formation of the corresponding reduction products. A facilitated ligand modification process was shown to be critical to the success of the reaction.

CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES

The invention relates to 6-substituted isoquinolone derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and composit

CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE DERIVATIVES

The invention relates to 6-substituted isoquinoline derivatives of the Formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES

The invention relates to 6-substituted isoquinoline and isoquinolinone derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE

The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I); useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS

The invention relates to 6-piperidinyl-substituted isoquinolone derivatives of the formula (I) or isoquinoline derivatives of the formula (I′) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated pho

CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS

The invention relates to 6-cyclohexylamine-substituted isoquinolone derivatives of the formula (I) or isoquinoline derivatives of the formula (I’) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

Synthesis and SAR exploration of dinapsoline analogues

Dinapsoline is a full D1 dopamine receptor agonist that produces robust rotational activity in the unilateral 6-OHDA rat model. This compound is orally active, and shows a low tendency to cause tolerance in rat models. The active enantiomer was determined to have the S-(+) configuration, and the opposite enantiomer is essentially devoid of biological activity. Taken together, dinapsoline has significant metabolic and pharmacological advantages over previous D1 agonists. In an attempt to define the structure-activity relationships (SARs) and to map out the key elements surrounding the unique structure of dinapsoline, core analogues and substitution analogues of the parent tetracyclic condensed ring structure were prepared. Based on a recently developed synthesis of dinapsoline and its enantiomers, both core and substitution analogues on all four rings (A, B′, C and D ring) of dinapsoline were synthesized. It was found that affinity for both D1and D2 receptors was decreased by most substituents on the A, B′, and C rings, whereas D ring substitutions preserved much of the dopamine receptor binding activity.